ProMIS Neurosciences, Inc. (NASDAQ:PMN) Insider Buys $14,550.00 in Stock

ProMIS Neurosciences, Inc. (NASDAQ:PMN) insider Neil Cashman bought 15,000 shares of the business’s stock in a transaction on Monday, February 10th. The stock was bought at an average cost of $0.97 per share, with a total value of $14,550.00. Following the transaction, the insider now owns 16,617 shares in the company, valued at $16,118.49. This trade represents a 927.64 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

ProMIS Neurosciences Trading Down 0.7 %

NASDAQ:PMN opened at $0.95 on Friday. ProMIS Neurosciences, Inc. has a 12 month low of $0.87 and a 12 month high of $2.61. The company has a market cap of $31.06 million, a PE ratio of -9.50 and a beta of 0.56. The company has a 50 day simple moving average of $0.94 and a two-hundred day simple moving average of $1.08.

Institutional Investors Weigh In On ProMIS Neurosciences

A number of large investors have recently added to or reduced their stakes in PMN. Great Point Partners LLC bought a new stake in shares of ProMIS Neurosciences during the 3rd quarter valued at $3,488,000. Ally Bridge Group NY LLC increased its stake in shares of ProMIS Neurosciences by 50.3% in the 3rd quarter. Ally Bridge Group NY LLC now owns 1,592,605 shares of the company’s stock worth $1,991,000 after purchasing an additional 533,023 shares in the last quarter. Finally, Sphera Funds Management LTD. increased its stake in shares of ProMIS Neurosciences by 6.3% in the 3rd quarter. Sphera Funds Management LTD. now owns 1,929,297 shares of the company’s stock worth $2,412,000 after purchasing an additional 115,084 shares in the last quarter. Institutional investors own 50.13% of the company’s stock.

About ProMIS Neurosciences

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.